4 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 44 points (0.3%) at 15,464 as of Tuesday, Aug. 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,183 issues advancing vs. 1,800 declining with 78 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Osiris Therapeutics ( OSIR), up 112.4%, Novo Nordisk A/S ( NVO), up 0.7% and AstraZeneca ( AZN), up 0.6%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Regeneron Pharmaceuticals is down $3.05 (-1.2%) to $242.91 on light volume. Thus far, 297,421 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 810,200 shares. The stock has ranged in price between $242.02-$245.96 after having opened the day at $245.59 as compared to the previous trading day's close of $245.96.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $24.2 billion and is part of the health care sector. Shares are up 43.8% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round